Online inquiry

IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9419MR)

This product GTTS-WQ9419MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets KLRC1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001304448.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3821
UniProt ID P26715
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9419MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9077MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ12893MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ3098MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ3031MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ3578MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ15384MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ9345MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ9145MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMGN-289
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW